Trinity Biotech ADR Stock
Trinity Biotech ADR Stock
Pros and Cons of Trinity Biotech ADR in the next few years
Pros
Cons
Performance of Trinity Biotech ADR vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Trinity Biotech ADR | - | - | - | - | - | - | - |
Gritstone Oncology Inc | 13.680% | 12.684% | -27.568% | -63.946% | -56.728% | -89.294% | - |
Avid Bioservices Inc | 0.700% | 10.000% | 20.168% | -54.747% | 17.213% | -59.605% | 74.561% |
Pacira Pharmaceuticals | 3.310% | 2.542% | -9.023% | -41.546% | -18.792% | -53.010% | -42.850% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon an initial overview of Trinity Biotech's financial statements and ratios, it's evident that the company, trading under the symbol TRIB within the pharmaceuticals industry, is facing several financial challenges. The negative total stockholder equity figures across multiple years and a net income trajectory that has been in the negative zone indicate underlying financial stress. These snapshots raise questions regarding the company's profitability, debt management, and overall financial stability.
Delving into a more detailed analysis uncovers several pros and cons:
*Pros: *
Comments